A5005058951- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Head and Neck Cancer Studies
- Salivary Gland Tumors Diagnosis and Treatment
- Lung Cancer Diagnosis and Treatment
- Cancer-related gene regulation
- Carbon Dioxide Capture Technologies
- Boron Compounds in Chemistry
- HER2/EGFR in Cancer Research
- Occupational and environmental lung diseases
- Insect Resistance and Genetics
- Melanoma and MAPK Pathways
- Gastric Cancer Management and Outcomes
- Cell Adhesion Molecules Research
- Adsorption and Cooling Systems
- Nanoplatforms for cancer theranostics
- Colorectal Cancer Treatments and Studies
- Ear and Head Tumors
- Inflammatory Biomarkers in Disease Prognosis
- Congenital Diaphragmatic Hernia Studies
- Cancer Genomics and Diagnostics
- Pleural and Pulmonary Diseases
- Cancer therapeutics and mechanisms
- Cancer Research and Treatments
- Cancer Immunotherapy and Biomarkers
Shanghai Pulmonary Hospital
2009-2025
Tongji University
2009-2025
// Jiayu Li 1 , Xuefei 2 Shengxiang Ren Xiaoxia Chen Yishi Zhang Fei Zhou Mingchuan Zhao Chao Xiu 3 Ningning Cheng Yinmin 4 Caicun Fred R. Hirsch 5 Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School Medicine, Cancer Institute, Shanghai, China Lung and Immunology, University, Respiration, Zaozhuang Municipal Zaozhuang, Shandong, Central Laboratory, Departments Medicine Pathology, Colorado Center, Aurora, Colorado, USA. Correspondence to: Dr. Zhou, e-mail:...
Abstract Background: The anti-PD-1 antibody pembrolizumab plus platinum-based chemotherapy is a standard of care treatment option for metastatic squamous NSCLC without targetable genetic aberrations and regardless PD-L1 status. Despite advancements, there remains an unmet need patients with NSCLC. Trophoblast cell-surface antigen 2 (TROP2), transmembrane glycoprotein involved in cancer growth invasion, has emerged as promising therapeutic target Sac-TMT (also known MK-2870/SKB264)...
The present study aimed to explore the role of integrin β1 and relevant signaling pathways in acquired gefitinib resistance non‑small cell lung cancer (NSCLC). inhibitory effects gefitinib, with or without LY294002, on cellular proliferation were evaluated by 3‑(4,5‑dimethylthiazol‑2‑yl) 2,5‑diphenyltetrazolium bromide assay. Cell cycle progression apoptosis analyzed flow cytometry, while western blotting was used evaluate expression EGFR, phosphorylated (phospho)‑EGFR, protein kinase B...
Abstract Background Recurrent malignant pleural effusion (MPE) resulting from non‐small‐cell lung cancer (NSCLC) is easily refractory to conventional therapeutics and lacks predictive markers. The cellular or genetic signatures of recurrent MPE still remain largely uncertain. Methods 16 NSCLC patients with effusions were recruited, followed by corresponding treatments based on primary tumours. Non‐recurrent was determined after 3–6 weeks treatments. status verified computer tomography (CT)...
Small molecular inhibitors of the epidermal growth factor receptor (EGFR) have been extensively studied in non-small cell lung cancer (NSCLC) patients. The discovery biomarkers that identify subgroups NSCLC patients benefiting from EGFR tyrosine kinase inhibitor (TKI) has become an important area investigation. Recent studies suggested epithelial-mesenchymal transition (EMT) tumours decreases cellular requirements for signalling pathway, and this may provide a signature to define those most...
Mosquito coils, which are commonly used as residential insecticides in Asia, contain different concentrations of octachlorodipropyl ether (S‑2) a synergist or an active ingredient. As bis(chloromethyl) (BCME) is extremely potent lung carcinogen that can be produced by the thermolytic degradation S‑2, contact with mosquito coils likely to expose individuals certain level BCME, and therefore increase risk cancer. However, significance exposure uncertain, clinical epidemiological studies...
8015 Background: Docetaxel (75 mg/m 2 ) has been reported as first-line and maintenance treatment for Western population with advanced NSCLC. Different doses of docetaxel (60 are currently delivered in Asian population. Pharmacogenomics alterations taxanes disposition different ethnic groups may explain this difference. TFINE study was to evaluate the efficacy, safety, tolerability setting, identify preferable dose Methods: Previously untreated patients, aged between 18 75 years,...
Aim: To observe the therapeutic efficacy and prognostic factors that influence survival rates in non-small cell lung cancer (NSCLC) patients with multiple brain metastases (BMs, more than three less ten). Methods: Retrospective analyses were conducted on clinical data of 209 NSCLC BMs admitted to our hospital between March 2007 November 2012. All BM received whole-brain radiotherapy. Two hundred combined chemotherapy during treatment process; 99 targeted drug therapy; nine got only...
11068 Background: LIBRETTO-431 (NCT04194944), a randomized phase 3 trial, compared first-line selpercatinib to platinum-based chemotherapy +/- pembrolizumab (pembro). Selpercatinib, highly selective and potent CNS penetrant RET inhibitor, is approved for the treatment of advanced fusion+ NSCLC. This analysis reported NSCLC symptoms HRQoL from LIBRETTO-431. Methods: used data (cut-off date: May 01, 2023) intent-to-treat (ITT) pembro subpopulation [selpercatinib (n=129); + (control, n=83)]...